Core C: Uganda

核心C：乌干达

• 批准号: 10457724
• 负责人: Immaculate Lillian Nankya
• 金额: $ 47.93万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-01 至 2027-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10457724
• 关键词: AIDS clinical trial group; AIDS prevention; AIDS related cancer; AIDS/HIV problem; Accreditation; Achievement; Acquired Immunodeficiency Syndrome; Address; Affect; Africa; American; Biological Assay; Blood; Cardiovascular system; Certification; Clinical; Clinical Immunology; Clinical Research; Clinical Trials Unit; Cohort Studies; Collaborations; Complement; Complication; Contraceptive methods; Doctor of Philosophy; Drug resistance; Equipment; Fogarty International Center; Funding; Gender; Genotype; HIV; HIV Infections; HIV drug resistance; HIV/TB; Health Professional; Hormonal; Hospitals; Human Resources; Immunologics; Immunology; Infection; International; International Cooperation; Investigational Drugs; Investments; Joints; Laboratories; Lead; Measurement; Measures; Microbiology; Modeling; Modernization; Molecular; Molecular Virology; Monitor; Observational Study; Pathogenesis; Pathologist; Patients; Phenotype; Prevention Research; RNA; Research; Research Personnel; Research Support; Research Training; Role; Science; Scientist; Site; Spottings; Students; Techniques; Technology; Technology Transfer; Testing; Training; Translational Research; Treatment Failure; Uganda; Universities; Vertical Disease Transmission; Virus Integration; Woman; base; clinical investigation; co-infection; college; comorbidity; cost effective; doctoral student; experience; genome sequencing; graduate student; immunological intervention; implementation research; improved; innovation; integration site; latent HIV reservoir; men; microbiome; next generation sequencing; pre-clinical; pre-exposure prophylaxis; programs; research study; sex; training opportunity; training project; translational study; virology; whole genome

PROJECT SUMMARY/ABSTRACT – UGANDA CORE C The RUSTBELT CFAR Uganda Core C reached several impressive milestones: (i) The core was selected in 2017 as one of 2 lead National HIV drug resistance testing labs for genotyping second-line ART treatment failures. (ii) We added next gen sequencing (NGS) to traditional Sanger-based sequencing for HIV drug resistance testing. (iii) We achieved College of American Pathologists’ (CAP) accreditation in 2017 (recertified in 2019) for HIV drug resistance testing. (iv) The EDITS assay to measure the HIV RNA reservoir was transferred from CWRU. (v) Core C advanced HIV Cure, HIV-TB, HIV-associated malignancies, and cardiovascular complication projects. (vi) Core C became a training and project site for Makerere University (MU) graduate students. The research collaboration between MU and CWRU celebrated its 30th year in 2018 and is widely recognized as a model for successful international cooperation and progress. Currently over 200 Ugandan scientists and health care professionals are engaged in CFAR collaborative programs at the Joint Clinical Research Centre (JCRC), MU, and Mulago Hospital in Kampala. Due to CFAR investments, cutting edge molecular HIV virology and clinical immunology research in Uganda became possible. The integration of the University of Pittsburgh (Pitt) and CWRU/UHMC to form the RUSTBELT CFAR significantly expands Core C’s research and training opportunities for Ugandan, CWRU, and Pitt trainees and researchers by including a broader scope of translational, clinical, and implementation research. Based on these milestones, Core C’s aims are (1) Provide virologic and immunologic research support for studies on HIV complications and the role of gender on HIV infection in Uganda. Core C will incorporate new innovative techniques and assays to study the role of gender in HIV infection and its complications in the following studies: the impact of hormonal status and contraception on the size of the HIV reservoir, the role of gender in HIV co-infection, cardiovascular complications of HIV, HIV associated malignancies, and the microbiome in HIV patients. (2) Expand research on the impact of HIV drug resistance on HIV prevention in Uganda. The collaboration with the team at Pitt brings on board a wealth of expertise which will strengthen Core C in HIV drug resistance and HIV prevention research in Uganda. (3) Provide support for new Translational HIV Research in Uganda for RUSTBELT CFAR investigators. Core C will build on the clinical research experience in Uganda by CWRU’s TB Research Unit and the AIDS Clinical Trials Unit. (4) Continue to provide biomedical training for Ugandan Master and PhD students. Core C through Fogarty D43-010319 "Microbiology and Immunology Training for HIV and HIV-Related Research in Uganda” (MITHU (Boom, Karn, & Joloba, Co-PI). Integration of Pitt with the CWRU/UHMC CFAR to form the RUSTBELT CFAR significantly expands Core C’s research and training opportunities in Uganda. Dr. Urvi Parikh (Core C Director from Pitt) will complement Dr. Immaculate Nankya (Core C Director from JCRC) and help expand opportunities for HIV drug resistance research in Uganda. We are actively building on the expertise in HIV reservoir measurements, viral integration site analysis, whole genome sequencing, and drug resistance research at Pitt led by Dr. John Mellors (Core E). RUSTBELT CFAR investigators will engage with colleagues at Makerere University and the JCRC in studies of HIV pathogenesis, persistence, cure (Core E), HIV co-infection, and provide expanded training opportunities for Ugandan investigators in US-based CFAR laboratories (Cores B, E, and F).

项目摘要/摘要 - 乌干达核心C Rustbelt CFAR乌干达核心C达到了几个令人印象深刻的里程碑：（i）核心于2017年选拔 作为2个主要国家HIV耐药性测试实验室之一，用于基因分型二线艺术治疗失败。 （ii） 我们将下一个Gen测序（NGS）添加到基于Sanger的传统测序中，以进行HIV耐药性测试。 （iii）我们在2017年获得了美国病理学家学院（CAP）认证（2019年重新认证） 电阻测试。 （iv）测量HIV RNA库的编辑测定是从CWRU转移的。 （v） 核心C先进的HIV治疗，HIV-TB，与HIV相关的恶性肿瘤和心血管并发症项目。 （vi）Core C成为Makerere University（MU）研究生的培训和项目地点。研究 MU和CWRU之间的合作庆祝了2018年的30年，并被广泛认为是 成功的国际合作与进步。目前有200多名乌干达科学家和医疗保健 专业人员在MU联合临床研究中心（JCRC）的CFAR合作计划中。 和坎帕拉的Mulago医院。由于CFAR研究，尖端分子HIV病毒学和临床 乌干达的免疫学研究变得可能是可能的。匹兹堡大学（皮特）和 CWRU/UHMC形成Rustbelt CFAR大大扩大了Core C的研究和培训机会 对于乌干达，CWRU和皮特学员和研究人员，包括更广泛的翻译，临床， 和实施研究。基于这些里程碑，Core C的目标是（1）提供病毒学和 免疫学研究支持HIV并发症研究以及性别对HIV感染的作用 乌干达。核心C将纳入新的创新技术和测定，以研究性别在艾滋病毒中的作用 感染及其在以下研究中的并发症：马匹状态和避孕对 艾滋病毒水库的大小，性别在艾滋病毒共同感染中的作用，艾滋病毒的心血管并发症，艾滋病毒 相关的恶性肿瘤和HIV患者的微生物组。 （2）扩大对HIV药物影响的研究 乌干达预防艾滋病毒的抵抗。与皮特团队的合作带来了很多 将在乌干达加强艾滋病毒耐药性和艾滋病毒预防研究中的核心C的专业知识。 （3） 为Rustbelt CFAR调查人员提供支持在乌干达的新转化HIV研究的支持。 Core C Will 基于CWRU的结核病研究部门在乌干达的临床研究经验和艾滋病临床试验基础 单元。 （4）继续为乌干达硕士和博士生提供生物医学培训。通过fogarty核心C D43-010319“乌干达的艾滋病毒和与艾滋病毒相关的研究的微生物学和免疫学培训”（密特 （Boom，Karn，＆Joloba，Co-Pi）。将PITT与CWRU/UHMC CFAR集成以形成Rustbelt CFAR。 大大扩大了Core C在乌干达的研究和培训机会。 Urvi Parikh博士（核心C主任 来自皮特（Pitt）的来自Pitt）将补充圣母无原罪Nankya（JCRC的Core C主任），并帮助扩大机会 用于乌干达的艾滋病毒抗药性研究。我们正在积极建立艾滋病毒水库专业知识 PITT的测量，病毒整合位点分析，整个基因组测序和耐药性研究 由约翰·梅洛斯（John Mellors）博士领导（核心E）。 Rustbelt CFAR调查人员将与Makerere的同事互动 大学和JCRC在HIV发病机理，持久性，治疗（核心E），HIV共同感染和 为美国CFAR实验室的乌干达调查人员提供扩大的培训机会（核心B，E，E， 和f）。